RU2006114791A - Продленные режимы трехфазных контрацептивов - Google Patents
Продленные режимы трехфазных контрацептивов Download PDFInfo
- Publication number
- RU2006114791A RU2006114791A RU2006114791/14A RU2006114791A RU2006114791A RU 2006114791 A RU2006114791 A RU 2006114791A RU 2006114791/14 A RU2006114791/14 A RU 2006114791/14A RU 2006114791 A RU2006114791 A RU 2006114791A RU 2006114791 A RU2006114791 A RU 2006114791A
- Authority
- RU
- Russia
- Prior art keywords
- phase
- days
- norgestimate
- progestin
- estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Способ контрацепции, предусматривающий стадию:
введения женщине детородного возраста комбинации эстрогена и прогестина в течение по меньшей мере 42 дней подряд, после чего следует период без приема гормонов от 4 до 8 дней, указанные эстроген и прогестин вводятся ежедневно в дозе, эффективной для контрацепции, в течение по меньшей мере двух циклов, состоящих по меньшей мере из 21 дня, где доза эстрогена остается постоянной в течение каждого цикла, а доза прогестина увеличивается в три фазы в течение каждого дневного цикла.
2. Способ по п.1, где в течение каждого цикла эстроген ежедневно вводят в дозе, эквивалентной 23-28 мкг этинилэстрадиола, а прогестин вводят в первой фазе в ежедневной дозе, эквивалентной 0,03-0,25 мг норгестимата, затем следует вторая фаза в ежедневной дозе, эквивалентной 0,1-0,35 мг норгестимата, затем следует третья фаза в ежедневной дозе, эквивалентной 0,15-0,50 мг норгестимата.
3. Способ по п.1, где каждая фаза имеет одинаковую продолжительность.
4. Способ по п.2, где эстроген и прогестин вводят в течение четырех 21-дневных циклов, составляющих в общей сложности 84 дня непрерывного введения эстрогена и прогестина.
5. Способ по п.4, где в течение каждого 21-дневного цикла ежедневно вводят 25 мкг этинилэстрадиола и ежедневно вводят 0,180 мг норгестимата в первой фазе из 7 дней, затем ежедневно вводят 0,215 мг норгестимата во второй фазе из 7 дней, затем ежедневно вводят 0,250 мг норгестимата в третьей фазе из 7 дней.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50753603P | 2003-10-01 | 2003-10-01 | |
| US60/507,536 | 2003-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006114791A true RU2006114791A (ru) | 2007-11-27 |
Family
ID=34421627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006114791/14A RU2006114791A (ru) | 2003-10-01 | 2004-09-30 | Продленные режимы трехфазных контрацептивов |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050090475A1 (ru) |
| EP (1) | EP1673094A1 (ru) |
| JP (1) | JP2007507534A (ru) |
| KR (1) | KR20060129175A (ru) |
| CN (1) | CN1863537A (ru) |
| AU (1) | AU2004277998A1 (ru) |
| BR (1) | BRPI0414945A (ru) |
| CA (1) | CA2540697A1 (ru) |
| CO (1) | CO5690602A2 (ru) |
| NO (1) | NO20061937L (ru) |
| NZ (1) | NZ545969A (ru) |
| RU (1) | RU2006114791A (ru) |
| WO (1) | WO2005032558A1 (ru) |
| ZA (1) | ZA200603416B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| WO2003049744A1 (en) | 2001-12-05 | 2003-06-19 | Barr Laboratories, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| EP1624848A4 (en) | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
| WO2005007112A2 (en) | 2003-07-16 | 2005-01-27 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| US20070111975A1 (en) * | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| TW200626161A (en) * | 2004-10-07 | 2006-08-01 | Duramed Pharmaceuticals Inc | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| MX2008011074A (es) * | 2006-03-02 | 2008-09-10 | Warner Chilcott Co Inc | Metodo anticonceptivo oral multifasico de ciclo prolongado. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US36247A (en) * | 1862-08-19 | Improvement in car-couplings | ||
| US4264575A (en) * | 1979-07-16 | 1981-04-28 | Eli Lilly And Company | Contraceptive methods and compositions |
| US4390531A (en) * | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| US5043331A (en) * | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
| DE3929376C1 (ru) * | 1989-09-05 | 1991-04-18 | E.I. Du Pont De Nemours And Co., Wilmington, Del., Us | |
| IE62665B1 (en) * | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5439913A (en) * | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| DE4344463A1 (de) * | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
| DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| US6506390B2 (en) * | 1996-06-25 | 2003-01-14 | Akzo Nobel | Progestogen-anti-progestogen regimens |
| US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
| US6451778B1 (en) * | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
| US6479475B1 (en) * | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
| DE19705229C2 (de) * | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| AU9028098A (en) * | 1997-08-27 | 1999-03-16 | Ortho Pharmaceutical Corporation | Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6326392B1 (en) * | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| US6329416B1 (en) * | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| US20020177580A1 (en) * | 2001-05-23 | 2002-11-28 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
| US20030018018A1 (en) * | 2001-07-10 | 2003-01-23 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea |
-
2004
- 2004-09-30 EP EP04789490A patent/EP1673094A1/en not_active Withdrawn
- 2004-09-30 JP JP2006534189A patent/JP2007507534A/ja active Pending
- 2004-09-30 CN CNA2004800289124A patent/CN1863537A/zh active Pending
- 2004-09-30 WO PCT/US2004/032497 patent/WO2005032558A1/en active Application Filing
- 2004-09-30 NZ NZ545969A patent/NZ545969A/en not_active IP Right Cessation
- 2004-09-30 RU RU2006114791/14A patent/RU2006114791A/ru not_active Application Discontinuation
- 2004-09-30 BR BRPI0414945-9A patent/BRPI0414945A/pt not_active IP Right Cessation
- 2004-09-30 US US10/955,276 patent/US20050090475A1/en not_active Abandoned
- 2004-09-30 KR KR1020067007018A patent/KR20060129175A/ko not_active Application Discontinuation
- 2004-09-30 AU AU2004277998A patent/AU2004277998A1/en not_active Abandoned
- 2004-09-30 CA CA002540697A patent/CA2540697A1/en not_active Abandoned
-
2006
- 2006-04-21 CO CO06037928A patent/CO5690602A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA200603416A patent/ZA200603416B/en unknown
- 2006-05-02 NO NO20061937A patent/NO20061937L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200603416B (en) | 2007-09-26 |
| NZ545969A (en) | 2008-07-31 |
| WO2005032558A1 (en) | 2005-04-14 |
| BRPI0414945A (pt) | 2006-11-07 |
| NO20061937L (no) | 2006-06-29 |
| CA2540697A1 (en) | 2005-04-14 |
| AU2004277998A1 (en) | 2005-04-14 |
| CO5690602A2 (es) | 2006-10-31 |
| US20050090475A1 (en) | 2005-04-28 |
| EP1673094A1 (en) | 2006-06-28 |
| JP2007507534A (ja) | 2007-03-29 |
| CN1863537A (zh) | 2006-11-15 |
| KR20060129175A (ko) | 2006-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2558030T3 (es) | Método anticonceptivo oral multifásico de ciclo prolongado | |
| KR100186780B1 (ko) | 피임제제 | |
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| RU2001117204A (ru) | Трехфазный пероральный контрацептив | |
| FI99083C (fi) | Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita | |
| TR200101826T2 (tr) | Üç-fazlı ağızdan alınan gebelik önleyici ilaç | |
| WO2006042021B1 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| EA200300338A1 (ru) | Способ контрацепции и формы введения контрацептивов | |
| JP2007535519A5 (ru) | ||
| JP2005516913A5 (ru) | ||
| RU99101114A (ru) | Схемы приема прогестогена-антипрогестогена | |
| RU2008105834A (ru) | Пероральная контрацепция с использованием тримегестона | |
| JP2010180236A5 (ru) | ||
| RU96119957A (ru) | Фармацевтический комбинированный препарат для гормональной контрацепции | |
| KR19990076685A (ko) | 게스타겐 및 에스트로겐의 배합을 포함하는 암컷 포유동물용 피임 방법 및 키트 | |
| ES2397983T3 (es) | Procedimiento anticonceptivo oral multifásico de ciclo prolongado | |
| RU2006114791A (ru) | Продленные режимы трехфазных контрацептивов | |
| RU2008138166A (ru) | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза | |
| ATE278406T1 (de) | Orales contrazeptivum | |
| ATE249222T1 (de) | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten | |
| RU2005128284A (ru) | Продленные режимы чрескожной контрацепции | |
| EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
| RU96102023A (ru) | Гормональное средство для лечения угрей | |
| RU2001131730A (ru) | Применение антипрогестогенов в комбинированной терапии | |
| DK1937274T3 (da) | Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090318 |